European Federation of Pharmaceutical Industries and Associations

European Federation of Pharmaceutical Industries and Associations
Canada's Research-Based Pharmaceutical Companies

Canada's Research-Based Pharmaceutical Companies

September 29, 2014 10:49 ET

EFPIA and Rx&D Welcome Announcement Indicating Finalisation of CETA Text as a Step to Benefit Patients and Innovation in Future

BRUSSELS, BELGIUM and OTTAWA, ONTARIO--(Marketwired - Sept. 29, 2014) - The European Federation of Pharmaceutical Industries and Associations (EFPIA) and Canada's Research-Based Pharmaceutical Companies (Rx&D) welcome last week's announcement regarding the successful finalisation of the text for the Comprehensive Economic and Trade Agreement (CETA). The news was shared last week during the EU-Canada Summit in Ottawa.

This is a landmark agreement, the first free trade agreement with any G8 country. EFPIA and Rx&D believe this agreement will, once in place, be beneficial to patients on both sides of the Atlantic, as well as for innovation and research.

Richard Bergström, Director General of EFPIA said: "The agreement marks the ongoing EU commitment to free trade and support innovation and knowledge-based industries. We look forward to working with all relevant stakeholders to ensure that this agreement delivers for patients and innovation in both the EU and Canada."

"CETA represents an important step towards putting Canada on the same playing field as its major trading partners," added Russell Williams, President, Rx&D. "It is a clear sign that Canada wants to do business with its European counterparts. In our industry, the business model is shifting towards more partnerships. CETA is a great example of this. We now look to the governments involved to move swiftly on implementation; this is good for all the countries involved, and it's good for Canadians."

The CETA agreement is expected to foster growth and employment for both the EU and Canadian economies. EFPIA welcomes the publication of the finalised CETA text in the future. We also understand that the agreement will not impact on access to medicines in developing countries.


EFPIA represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 40 leading pharmaceutical companies, EFPIA provides the voice of 1,900 companies committed to researching, developing and bringing new medicines to improve health and quality of life around the world. The pharmaceutical industry invests EUR30.6 billion on research and development per year in Europe and directly employs 690,000 people including 115,000 in R&D units in Europe.

EFPIA members are committed to delivering innovative medicines to address unmet needs of patients and reducing the burden of chronic diseases for Europe's ageing population. EFPIA believes in close cooperation with its stakeholders to help create sustainable healthcare systems and to develop prompt responses to health threats in Europe.

Find EFPIA Online

About Rx&D

Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents the men and women working for more than 50 member companies which invest more than $1 billion in research and development each year to fuel Canada's knowledge-based economy, contributing over $3 billion to the Canadian economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, private payers, healthcare professionals and stakeholders in a highly ethical manner.



Contact Information


Keyword Cloud

View Website